Clinical trials of endothelin antagonists in heart failure: publication is good for the public health.
نویسندگان
چکیده
The failure of endothelin antagonists to show benefit in heart failure cannot be understood until all the clinical trials are fully published.
منابع مشابه
Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve?
In the early 1990s, within three years of cloning of endothelin receptors, orally active endothelin receptor antagonists (ERAs) were tested in humans and the first clinical trial of ERA therapy in humans was published in 1995. ERAs were subsequently tested in clinical trials involving heart failure, pulmonary arterial hypertension, resistant arterial hypertension, stroke/subarachnoid hemorrhage...
متن کاملLetter to the Editor: "Evaluate the effects of curcumin on the prevention of atrial and ventricular arrhythmias and heart failure in patients with unstable angina"
Dear editor In a recent issue of the journal, Dastani et al. (2019) evaluate the effects of curcumin on the prevention of atrial and ventricular arrhythmias and heart failure in patients with unstable angina. Despite the fact that the topic was interesting, there were some defects and we wish to call to your attention important factual issues in this publication. The most cr...
متن کاملThalassemia Associated Pulmonary Hypertension
Cardiac disease is the main cause of death in both forms of thalassemia; thalassemia major (TM) and thalassemia intermedia (TI). Pulmonary hypertension (PH) is one of the cardiopulmonary morbidities with high mortality that, if not treated, may trigger right-sided heart failure and premature death. PH is defined as a mean pulmonary artery pressure of ≥25 mmHg at rest or ≥30 mmHg during exercise...
متن کامل[Treatment of heart failure: an update].
During the last years, the results of several trials on heart failure treatment were published or presented at international meetings. The new perspectives concern drug therapy and non-pharmacological strategies, such as cardioverter-defibrillators, biventricular resynchronization and implantable assist devices. Trials on beta-blockers extended the indication to patients with advanced heart fai...
متن کاملSafety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertension
Pulmonary arterial hypertension is a progressive, debilitating disease caused by a dysregulation of the pulmonary vascular tone that inevitably leads to right heart failure and death without treatment. Until relatively recently, the treatment options for those afflicted by pulmonary arterial hypertension were limited; today, a greater understanding of the pathophysiology behind this disease has...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Heart
دوره 93 1 شماره
صفحات -
تاریخ انتشار 2007